Xiuhua Liao1, Zhou Li2, Xiyuan Dong2, Hanwang Zhang2. 1. Reproductive Medicine Centre, Women and Children's Hospital of Fujian Province Fuzhou 350000, Fujian, China ; Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China. 2. Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030, Hubei, China.
Abstract
UNLABELLED: Endometrial preparation with exogenous estrogen is a common practice in frozen-thawed embryo transfer (FET) cycles. The objective of this study was to compare the clinical outcomes of two endometrial preparation groups, oral estradiol valerate tablets (OEV) group versus vaginal estradiol (VE) tablets group, in inadequate endometrium patients. This retrospective, single-center, cohort study of patients undergoing FET treatment between Jan. 2012 and Jun. 2013, at an academic IVF center, included 247 patients (cycles) with endometrial thickness < 8 mm on day 13 of the hormone replacement cycle: OEV group included 69 patients (cycles) who received continuous OEV from day 1 onwards up to the day of progesterone supplement, while VE group included 178 patients (cycles) who taken OEV from day 1 to day 12, and used VE tablets from day 13 till the day of progesterone supplement. Patients in VE group required more days and higher dosage of estradiol, but had thinner endometrium on the day of transfer. However, the increase of endometrial thickness was more, when compared to OEV-treated patients. The implantation rate and pregnancy rate were, though not significantly, higher in VE group. CONCLUSIONS: Longer time of administration and higher dosage of estradiol usage did not have adverse effects on the clinical pregnancy rate. VE tablets may promote endometrial development and pregnancy success in FET cycles could not verify. Further study is needed to confirm the vaginal estradiol action on frozen-thawed embryo transfer cycles.
UNLABELLED: Endometrial preparation with exogenous estrogen is a common practice in frozen-thawed embryo transfer (FET) cycles. The objective of this study was to compare the clinical outcomes of two endometrial preparation groups, oral estradiol valerate tablets (OEV) group versus vaginal estradiol (VE) tablets group, in inadequate endometrium patients. This retrospective, single-center, cohort study of patients undergoing FET treatment between Jan. 2012 and Jun. 2013, at an academic IVF center, included 247 patients (cycles) with endometrial thickness < 8 mm on day 13 of the hormone replacement cycle: OEV group included 69 patients (cycles) who received continuous OEV from day 1 onwards up to the day of progesterone supplement, while VE group included 178 patients (cycles) who taken OEV from day 1 to day 12, and used VE tablets from day 13 till the day of progesterone supplement. Patients in VE group required more days and higher dosage of estradiol, but had thinner endometrium on the day of transfer. However, the increase of endometrial thickness was more, when compared to OEV-treated patients. The implantation rate and pregnancy rate were, though not significantly, higher in VE group. CONCLUSIONS: Longer time of administration and higher dosage of estradiol usage did not have adverse effects on the clinical pregnancy rate. VE tablets may promote endometrial development and pregnancy success in FET cycles could not verify. Further study is needed to confirm the vaginal estradiol action on frozen-thawed embryo transfer cycles.
Authors: Ghazala Sikandar Basir; Tina Poy Wing Lam; Wai sum O; Ming Tak Chau; Ernest Hung Yu Ng; Pak Chung Ho Journal: Fertil Steril Date: 2002-11 Impact factor: 7.329
Authors: Manuel Leal Almeida; Eric Saucedo de la Llata; Victor Batiza Resendiz; Roberto Santos Haliscak; Pedro Galache Vega; Samuel Hernández Ayup Journal: Ginecol Obstet Mex Date: 2004-03
Authors: C L Schmidt; D de Ziegler; C L Gagliardi; R W Mellon; F H Taney; M J Kuhar; J M Colon; G Weiss Journal: Fertil Steril Date: 1989-10 Impact factor: 7.329
Authors: D Navot; P A Bergh; M Williams; G J Garrisi; I Guzman; B Sandler; J Fox; P Schreiner-Engel; G E Hofmann; L Grunfeld Journal: J Clin Endocrinol Metab Date: 1991-02 Impact factor: 5.958
Authors: Randi H Goldman; Anna Greer; Catherine Racowsky; Leslie V Farland; Andrea Lanes; Ann Muir Thomas; Mark D Hornstein Journal: J Assist Reprod Genet Date: 2022-05-18 Impact factor: 3.357